Posts Tagged ‘FDA’

New obesity treatments promise to provide interesting news in the coming year. Two new drugs and at least one more medical device will come before FDA for approval this year. Other new treatments are in various stages of development. It’s hardly a flood of innovation, but considering how empty the toolbox is for treating obesity […]

FDA is trying to look at medical obesity devices through a patient’s eyes as they work with the medical device industry and payers to foster innovative medical technology for the treatment of obesity. At a two-day meeting jointly sponsored by  the FDA and the American Gastroenterological Association, Telba Irony presented research conducted by FDA into […]

Antibacterial soaps for consumer use will come off the market unless their makers prove that they actually live up to their claims. This would be the effect of a ruling published by FDA this week for a 180-day public comment period. People use these products to kill bacteria that cause illness and prevent their spread. […]

Emergency contraception for people with obesity might require a plan C. Data from the University of Edinburgh suggests that the emergency contraception product marketed as Plan B may not work for women with excess weight. Earlier this week, makers of a similar emergency contraception product in Europe revised the label to warn that it might […]

Orexigen announced today that good cardiovascular safety results for Contrave in the ongoing Light Study of cardiovascular outcomes will enable them to resubmit their product to FDA within a few weeks for approval as early as June, 2014. Contrave is a product for treating obesity that combines two older drugs — naltrexone and buproprion — in […]

The U.S. Food and Drug Administration (FDA) announced this week that they will declare trans fats unsafe for use in food products. This move comes seven years after New York City banned trans fats from restaurants. Back in 2006, some nutrition experts worried that banning trans fats would lead to consumption of more saturated fats. […]

The FDA Nonprescription Drugs Advisory Committee voted 10-6-2 Wednesday to recommend that Nasacort AQ nasal spray for nasal allergies be approved for sale in the U.S. without a prescription. Nasacort AQ is one of a group of nasal steroid sprays that experts generally agree are the most effective products for treating nasal allergies with an […]

The Danish maker of diabetes drugs, Novo Nordisk, said this week that their new obesity drug, liraglutide, could be ready by the end of 2014. Some business analysts are skeptical about the commercial potential of liraglutide in obesity because of modest efficacy — a view that the company rejects. In new clinical trial results from […]

Almost a year after FDA approved lorcaserin (Belviq®) for introduction in the U.S. and recommended that DEA label it as a class IV controlled substance, DEA has finally cleared the way by concurring with FDA’s recommendation. Class IV is the second least restrictive class for drugs with abuse potential and is the same class assigned […]

Labeling food to guide consumers to healthier choices is a tricky business. Ask Campbell’s, which had to execute a messy u-turn in 2011. Sales slumped when they went too far in reducing salt content for some of their soups and low-sodium claims backfired. A new study, though, suggests that deftly-executed salt labeling can help guide […]